High Dose PPI denied as non-formulary by Cigna?

Cigna's specific coverage criteria for high dose ppi are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denies High-Dose PPI as Non-Formulary

Cigna's formulary structure for PPIs typically places certain agents at preferred tiers and designates others as non-preferred or non-formulary. A non-formulary denial for a high-dose PPI most often occurs because (a) the specific PPI prescribed is not on Cigna's preferred drug list for the plan year, or (b) the high-dose strength or dosing configuration is not listed separately as a covered formulary item even when the standard-dose version of the same drug is covered. The denial is primarily administrative rather than a clinical determination.

## Why This Denial Is Appealable

Cigna's formularies include a formulary exception process. Exceptions are available when (a) no formulary PPI is medically appropriate for the patient — for example, because of a documented allergy, intolerance, or prior treatment failure with formulary alternatives — or (b) a formulary alternative would be clinically inferior for the patient's specific diagnosis. Non-formulary denials are among the most reversible appeal categories when the exception process is correctly invoked with clinical supporting documentation.

## Your Federal Appeal Rights

• Internal appeal and formulary exception: File a combined appeal and formulary exception request under ERISA §503 (employer plans) or applicable state law. These can often be submitted simultaneously to Cigna.
• External review: After exhausting internal remedies, ACA §2719 entitles you to independent external review. The standard window is approximately four months from the final internal denial. If clinical urgency exists — for example, active severe symptoms — request expedited review.

## Concrete Appeal Steps and Timeline

1. Confirm Cigna's current formulary and identify which PPIs are on the preferred tier for this plan. 2. Determine whether the patient has already tried any formulary-preferred PPI at the relevant dose level and, if so, document the outcome. 3. Have the prescribing clinician document why the specific non-formulary PPI at the high dose is medically necessary and why a formulary alternative is not adequate. 4. Submit a formulary exception request concurrent with a Level 1 internal appeal. 5. If both are denied, file for external IRO review within the window on the denial notice.

## Documentation to Gather

• Formulary alternative trial history: Documentation of prior trials of Cigna's preferred formulary PPIs — drug name, dose, duration, and reason for failure or intolerance — with supporting chart notes or pharmacy records.
• Clinical intolerance or allergy records: Allergy documentation or adverse event notes if the patient cannot use a formulary alternative for safety reasons.
• Diagnosis confirmation: Objective evidence (endoscopy, pH study, pathology) establishing the diagnosis that requires high-dose PPI therapy.
• Prescriber letter of medical necessity: A specific letter explaining why the non-formulary drug at the high dose is the medically appropriate choice for this patient's particular condition and treatment history.
• Step-therapy completion evidence: Records showing that any Cigna-required lower-tier or lower-dose alternative has already been adequately trialed.

## Criteria-Mapping Structure

Obtain Cigna's formulary exception criteria from the plan's Evidence of Coverage or pharmacy benefit document. Map each criterion to a specific clinical fact, pharmacy record, or physician statement. For a non-formulary exception, the two strongest arguments are (1) documented failure of every formulary alternative and (2) a prescriber attestation that the non-formulary drug is clinically necessary in a way that no formulary alternative can replicate. Present both if applicable.